Heres Your Guide to The Must-See Astronomy Events of 2025
| RGLS Stock | USD 1.26 0.02 1.61% |
Slightly above 52% of Regulus Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Regulus Therapeutics suggests that some traders are interested. Regulus Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Regulus Therapeutics' earnings reports, geopolitical events, and overall market trends.
Regulus |
How about that eclipse in 2024 Certainly, the Great North American Eclipse of April 8th 2024 was one for the ages, instilling the eclipse-chasing bug in many a new skywatching fan.
Read at sciencealert.com
 |
Regulus Therapeutics Fundamental Analysis
We analyze Regulus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regulus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regulus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Regulus Therapeutics is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Regulus Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Regulus Therapeutics stock to make a market-neutral strategy. Peer analysis of Regulus Therapeutics could also be used in its relative valuation, which is a method of valuing Regulus Therapeutics by comparing valuation metrics with similar companies.
Peers
Regulus Therapeutics Related Equities
| CLRB | Cellectar Biosciences | 4.17 | ||||
| TENX | Tenax Therapeutics | 1.26 | ||||
| VSTM | Verastem | 0.95 | ||||
| PULM | Pulmatrix | 2.13 |
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.